Target intelligence / Profile preview

Activated alloantigen-reactive T cell

Molecular classification
Other (Activated T lymphocyte; not a defined molecular class such as "receptor" or "enzyme")
01

Overview

An "activated alloantigen-reactive T cell" refers to a T lymphocyte (either CD4+ or CD8+) that has been stimulated by exposure to foreign (non-self) antigens, especially MHC molecules present on transplanted tissues or cells. This activation plays a central role in the immune response against allografts, driving processes such as organ transplant rejection and graft-versus-host disease. The activated state is characterized by upregulation of specific cell surface markers (including CD69, CD25, CD71, and HLA-DR), secretion of pro-inflammatory cytokines (such as IFN-γ and TNFα), and proliferation. While drugs can suppress these T cell responses, this is typically achieved by targeting broader pathways in T cell activation, and there is no single "activated alloantigen-reactive T cell receptor" entity. This concept describes a functional and phenotypic state, not an individual molecular target.

Other names
Activated alloreactive T cellActivated alloimmune T cellActivated allospecific T cell
02

Mechanism of action

Blockade of T cell activation (signal 1: TCR–MHC interaction, signal 2: co-stimulation) - T cell depletion - Cytokine pathway inhibition - Costimulatory blockade

03

Biological functions

Immune responseGraft rejectionAllorecognitionCytotoxicity (mainly for CD8+ T cells)Helper function (mainly for CD4+ T cells)Cytokine secretion
04

Disease associations

Transplant rejectionGraft-versus-host diseaseAutoimmunity (in some contexts)
05

Safety considerations

Global immunosuppression (increased risk of infection and malignancy)Cytokine release syndrome (when broad T cell activation is targeted)Off-target effects due to lack of specificity for only alloantigen-reactive T cells
06

Interacting drugs

Immunosuppressants (broadly: calcineurin inhibitors, corticosteroids, anti-thymocyte globulin, monoclonal antibodies such as anti-CD3, anti-CD52, CTLA-4-Ig, anti-CD25)
07

Biomarkers

CD69CD71CD25 (IL-2Rα)HLA-DRUpregulation of CD4 (for activated CD4+ T cells)Cytokine production (e.g., IFN-γ, TNFα)

Beyond the preview

Go deeper on Activated alloantigen-reactive T cell.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Activated alloantigen-reactive T cell.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call